Exonic polymorphism (rs315952, Ser133Ser) of interleukin 1 receptor antagonist (IL1RN) is related to overweigh/obese with hypertension

Yang, Seung-Ae; Seung-Ae Yang

doi:10.12965/jer.140155

J Exerc Rehabil > Volume 10(5);2014 > Article

Yang: Exonic polymorphism (rs315952, Ser133Ser) of interleukin 1 receptor antagonist (IL1RN) is related to overweigh/obese with hypertension

Original Article

Journal of Exercise Rehabilitation 2014; 10(5): 332-336.

Published online: October 31, 2014

DOI: https://doi.org/10.12965/jer.140155

Exonic polymorphism (rs315952, Ser133Ser) of interleukin 1 receptor antagonist (IL1RN) is related to overweigh/obese with hypertension

Seung-Ae Yang^*

College of Nursing, Sungshin Women’s University, Seoul, Korea

^*Corresponding author: Seung-Ae Yang, College of Nursing, Sungshin Women’s University, 55 Dobong-ro 76ga-gil, Gangbuk-gu, Seoul 142-732, Korea, Tel: +82-2-920-7728, Fax: +82-2-968-0560, E-mail: ewha63@sungshin.ac.kr

Received October 01, 2014 Accepted October 15, 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Recent studies demonstrated that interleukin 1 receptor antagonist (IL-1RN) plays an important role in metabolic effects. To investigate whether IL1RN polymorphisms are associated with obesity, two single nucleotide polymorphisms (SNPs) of the IL1RN gene [rs4251961 (-828, T> C) and rs315952 (Ser133Ser)] were analyzed in 122 overweigh/obese and 123 control subjects. Overweigh/obese subjects were classified according to body mass index (BMI). SNPStats was used to obtain odds ratios (ORs), 95% confidence intervals (CIs), and P values. Multiple logistic regression models (codominant1, codominant2, dominant, recessive, and log-additive) were conducted to analyze the genetic data. Synonymous SNP (rs315952) of the IL1RN gene was associated with overweigh/obese with hypertension (OR= 4.98, 95% CI= 1.74–14.19, P = 0.003 in codominant 1 model and OR= 3.98, 95% CI= 1.48–10.74, P= 0.0029 in dominant model). However, another SNP (rs4151961) did not show association with overweigh/obese or overweigh/obese with hypertension. These results suggest that exonic SNP of IL1RN (rs 315952, Ser133Ser) may be contributed to overweigh/obese with hyper-tension.

Keywords: IL1RN, Single nucleotide polymorphism, BMI, Overweigh/obese, Hypertension

INTRODUCTION

Exercise rehabilitation provides benefit to assisting in the physical state including blood pressure, blood sugar, and vessel elasticity in obesity (Lee et al., 2013). Although exercise rehabilitation is effective in obesity patients, there are various differences among obesity patients. Hence, it is important to find clinical characters of obesity patients in order to do exercise rehabilitation.

Obesity is the primary metabolic disorder and is well known to play a key role in the development of a number of metabolic abnormalities (Pi-Sunyer, 2002). Obesity increases the susceptibility of many diseases, such as type 2 diabetes mellitus, hypertension, and various cancers (Foss and Dyrstad, 2011). Obesity is characterized by an increased adipose tissue mass with large size and mature adipocytes. The obesity results in an imbalance between energy in-take and energy expenditure. Environmental, behavioral, and genetic factors have been known to contribute to the etiology of obesity (Foss and Dyrstad, 2011).

Interleukin 1 (IL1) is a regulator on inflammation and energy homeostasis. Previous studies investigated that the IL1 system was contributed to metabolism (Erion et al., 2014; Khalkhal et al., 2012). Interleukin 1 receptor antagonist (IL1RN) is included in the IL1 system. IL1RN is an acute-phase protein. IL1RN has an anti-inflammatory function by blocking the receptor for IL1A and IL1B without exerting any biological effect (Juge-Aubry and Meier, 2002).

Previous study revealed that IL1RN is associated with obesity (Somm et al., 2005). IL1RN showed high level in the serum of obese patients and overexpressed in white adipose tissue. Somm et al. (2005) reported that IL1RN knockout mice get leanness and obesity resistance. It indicated that IL1RN is an important regulator of adipogenesis, food intake, and energy expenditure in obesity. In this study, we investigated whether polymorphisms of the IL-1RN gene are associated with the development of obesity.

MATERIALS AND METHODS

Study subjects

Table 1 shows the clinical characteristics of subjects in this study. Subjects were recruited among participants who examined a general health check-up program. Each subject was calculated body mass index (BMI), systolic blood pressure (SBP), and diastolic blood pressure (DBP). BMI was also used by dividing the subject’s mass by the square of height (kg/m²). According to the classification of Korean Society for the Study of Obesity (underweight, BMI<18; normal, BMI 18 to<23; moderately obese, BMI 23 to<25; obesity I, BMI 25 to<30; obesity II, BMI≥30), subjects were divided into two subgroups, the overweigh/obese group (BMI≥23, n=122) and the normal group (18<BMI<23, n=123). And overweigh/obese subjects also divided into two subgroups, the overweigh/obese with hypertension group (>130 mmHg in SBP/>85 mmHg in DBP, n=40) and the overweigh/obese with non-hypertension group (<130 mmHg in SBP/<85 mmHg in DBP, n=98). The subjects with severe diseases, such as stroke, diabetic mellitus, and cancers were excluded in this study. Ethical approval of this study was obtained from the ethics review committee of Medical Research Institute, School of Medicine, Kyung Hee University, Seoul, Korea.

SNP selection and genotyping

We selected two SNPs in the IL1RN gene: [rs4251961 (-828, T>C) and rs315952 (Ser133Ser)]. They were searched from the SNP database in NCBI (http://www.ncbi.nlm.nih.gov/SNP, db141), and reviewed to select in the exon area and the promoter area. Peripheral blood of all subjects were collected in EDTA blood tube, stored in −20°C freezer before the extraction of genomic DNA. Genomic DNA was extracted with Roche DNA extraction kit (Indianapolis, IN, USA). Polymerase chain reactions (PCRs) of the SNPs were conducted using the following primers in the Table 2 to amplify target sequences including these SNPs [rs4251961 (-828, T>C) and rs315952 (Ser133Ser)]. PCR condition was 38 cycles at 94°C for 30 sec, 58°C for 30 sec, and 72°C for 30 sec. PCR products were identified with 1.8% agarose gel by electrophoresis. Each PCR product was analyzed by direct sequencing in order to obtain the genotype of each SNP. Direct sequencing, sequence sorting, and genetic data were performed by ABI PRISM 3730XL analyzer (PE Applied Biosystems, Foster City, CA, USA) and SeqManII software (DNASTAR, Madison, WI, USA).

Statistical analysis

Hardy-Weinberg equilibrium of each SNP was examined in SNPstats. SNPStats (http://bioinfo.iconcologia.net/index.php?-module=Snpstats) and SPSS 18.0 (SPSS Inc., Chicago, IL, USA) also were used to obtain odds ratios (ORs), 95% confidence intervals (CIs), and P values. Multiple logistic regression models were applied in the analysis of genotypes (Kim et al., 2014; Yang, 2013). The haplotype analysis in two SNPs of the IL1RN gene was analyzed with Haploview 4.2 software (Daly Lab, Cambridge, MA, USA). In the statistical analysis, P<0.05 was considered significant association.

RESULTS

Table 3 shows the genotype and allele frequencies of two SNPs (rs4251961 and rs315952) between the normal group and the overweigh/obese group. The risk of obesity was performed by logistic regression analysis. Genotype distributions of two SNPs in this study were in Hardy-Weinberg equilibrium in control subjects (rs4251961, P=1.00; rs315952, P=0.35, data not shown).

Frequencies of rs4251961 SNP genotype of the IL1RN gene in the normal group and the overweigh/obese group were 82.9%: 16.3%:0.8% and 85.2%:14.8%:0.0% (T/T genotype:T/C genotype:C/C genotype). Frequencies of rs4251961 SNP in the normal group and the overweigh/obese group were 91.1%:8.9% and 92.6%:7.4% (T allele:C allele).

Frequencies of rs315952 SNP genotype of the IL1RN gene in the normal group and the overweigh/obese group were 33.3%: 52.9%:13.8% and 32.0%:50.8%:17.2% (C/C genotype:C/T genotype:T/T genotype). Frequencies of rs315952 SNP in the normal group and the overweigh/obese group were 59.8%:40.2% and 57.4%:42.6% (C allele:T allele). There were differences of the genotype and allele frequencies in the normal group and the over-weigh/obese group. However, the differences did not show any significant association with obesity (P>0.05).

Two SNPs (rs4251961 and rs315952) of the IL1RN gene were analyzed for haplotype analysis using Haploview 4.2. There were four haplotypes (haplotype TC, frequency=0.57; haplotype TT, frequency=0.35; haplotype CT, frequency=0.07; haplotype CC, frequency=0.02) (Table 4). The difference between the normal group and the overweigh/obese group also did not show any association with obesity (P>0.05).

In clinical analysis, the overweigh/obese subjects were divided into two subgroup according to hypertension. Frequencies of rs315952 SNP genotype of the IL1RN gene in the overweigh/ obese with the non-hypertension group and the overweigh/obese with hypertension group were 36.7%:45.9%:17.4% and 15.0%: 67.5%:17.5% (C/C genotype:C/T genotype:T/T genotype). In the genotype distribution analysis, the difference of genotype frequency of rs315952 SNP showed significant association with hypertension [OR=4.98, 95% CI=1.74–14.19, P=0.003 in codominant 1 model (C/C genotype versus C/T genotype) and OR=3.98, 95% CI=1.48–10.74, P=0.0029 in dominant model (C/C genotype versus C/T genotype+T/T genotype), Table 5]. Another rs4251961 SNP was not associated with hypertension. The results suggested that rs315952 SNP was associated with overweigh/obese with hypertension.

DISCUSSION

In this study, we investigated the relationship between two SNPs (rs4251961 and rs315952) of IL1RN and obesity. IL1RN has biological function in human body. The IL1 system included several components, such as two agonists, IL1A and IL1A. The biological effects are exerted via the interleukin 1 receptor, type I (IL1R1). The binding of IL1 to IL1RI can be inhibited by the endogenous receptor antagonist IL1RN. The balance between IL1 and IL1RN plays an important role in the regulation of immune function (Arend, 2002; Dinarello, 1991; Strandberg et al., 2006). Previous study suggested that IL1 system was contributed to body fat accumulation in animal experiment. Matsuki et al. (2003) showed that increased IL1 activity due to IL1RN knockout results in resistance to obesity.

There were several genetic researches regarding the relationship between IL1RN polymorphisms and obesity (Andersson et al., 2009; Um et al., 2006). Um et al. (2004) investigated that 86 bp tandem repeat (VNTR) in the intron 2 of IL1RN was associated with obesity. The genotype and allele distributions of VNTR in IL1RN did not show association with obesity. However, Andersson et al. (2009) reported that rs4252041 SNP (3’-untranslated region, UTR) was associated with the primary outcome total fat mass and regional fat mass. We also investigated the relationship between IL1RN polymorphism (rs315952, Ser133Ser) and obesity and found significant association in obesity patients with hypertension. The rs315952 SNP of the IL1RN gene was investigated in various diseases including metabolic syndrome, systemic lupus erythematosus, ankylosing spondylitis, and osteoarthritis (Meyer et al., 2014; Oh et al., 2010; Tahmasebi et al., 2013; Wu et al., 2013). However, the 86 bp VNTR in the intron 2 of IL-1RN was not associated with essential hypertension in a Pakistani Pathan population (Khawaja et al., 2008).

In conclusion, we investigated the relationship between two SNPs (rs4251961 and rs315952) and obesity. One synonymous SNP (rs315952, Ser133Ser) of the IL1RN gene was associated with overweight/obesity with hypertension. The result suggested that IL1RN may be contributed to the development of obesity with hypertension. However, another cohort and functional studies will be needed to confirm this result in further study.

Notes

CONFLICT OF INTEREST

The authors have no conflicts of interest to declare.

REFERENCES

Andersson N, Strandberg L, Nilsson S, Ljungren O, Karlsson MK, Mell-strom D, Lorentzon M, Ohlsson C, Jansson JO. Variants of the interleukin-1 receptor antagonist gene are associated with fat mass in men. Int J Obes (Lond). 2009;33:525–533.

Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002;13:323–340.

Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood. 1991;77:1627–1652.

Erion JR, Wosiski-Kuhn M, Dey A, Hao S, Davis CL, Pollock NK, Stranahan AM. Obesity elicits interleukin 1-mediated deficits in hippocampal synaptic plasticity. J Neurosci. 2014;34:2618–2631.

Foss B, Dyrstad SM. Stress in obesity: cause or consequence? Med Hypotheses. 2011;77:7–10.

Juge-Aubry CE, Meier CA. Immunomodulatory actions of leptin. Mol Cell Endocrinol. 2002;194:1–7.

Khalkhal A, Haddar A, Semiane N, Mallek A, Abdelmalek A, Castex F, Gross R, Dahmani Y. Obesity, insulin resistance and diabetes in the sand rat exposed to a hypercaloric diet; possible protective effect for IL1-beta. C R Biol. 2012;335:271–278.

Khawaja MR, Taj F, Saleheen D, Ahmad U, Chohan MO, Jafar T, Frossard PM. Association study of two interleukin-1 gene loci with essential hypertension in a Pakistani Pathan population. J Hum Hypertens. 2008;22:60–62.

Kim SK, Kim YO, Lee BC, Yoo KH, Chung JH. Toll-like receptor 10-1-6 gene cluster polymorphisms are not associated with benign prostatic hyperplasia in korean population. Int Neurourol J. 2014;18:10–15.

Lee EO, Lee KH, Kozyreva O. The effect of complex exercise rehabilitation program on body composition, blood pressure, blood sugar, and vessel elasticity in elderly women with obesity. J Exerc Rehabil. 2013;9:514–519.

Matsuki T, Horai R, Sudo K, Iwakura Y. IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions. J Exp Med. 2003;198:877–888.

Meyer NJ, Ferguson JF, Feng R, Wang F, Patel PN, Li M, Xue C, Qu L, Liu Y, Boyd JH, et al. A Functional Synonymous Coding Variant in the IL-1RN Gene Is Associated with Survival in Septic Shock. Am J Respir Crit Care Med. 2014;190:656–664.

Oh IH, Oh C, Kim HJ, Choi JM, Yoon TY, Chung JH, Choe BK. Genetic associations of IL1RN polymorphisms with metabolic syndrome in a Korean population. Exp Clin Endocrinol Diabetes. 2010;118:333–337.

Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res. 2002;10:Suppl 2. 97S–104S.

Somm E, Henrichot E, Pernin A, Juge-Aubry CE, Muzzin P, Dayer JM, Nicklin MJ, Meier CA. Decreased fat mass in interleukin-1 receptor antagonist-deficient mice: impact on adipogenesis, food intake, and energy expenditure. Diabetes. 2005;54:3503–3509.

Strandberg L, Lorentzon M, Hellqvist A, Nilsson S, Wallenius V, Ohlsson C, Jansson JO. Interleukin-1 system gene polymorphisms are associated with fat mass in young men. J Clin Endocrinol Metab. 2006;91:2749–2754.

Tahmasebi Z1, Akbarian M, Mirkazemi S, Shahlaee A, Alizadeh Z, Amirzargar AA, Jamshidi AR, Ghoroghi S, Poursani S, Nourijelyani K, Mahmoudi M. Interleukin-1 gene cluster and IL-1 receptor polymorphisms in Iranian patients with systemic lupus erythematosus. Rheumatol Int. 2013;33:2591–2596.

Um JY, Kim HM, Mun SW, Song YS, Hong SH. Interleukin-1 receptor antagonist gene polymorphism and traditional classification in obese women. Int J Neurosci. 2006;116:39–53.

Um JY, Lee KM, Kim HM. Polymorphism of interleukin-1 receptor antagonist gene and obesity. Clin Chim Acta. 2004;340:173–177.

Wu X, Kondragunta V, Kornman KS, Wang HY, Duff GW, Renner JB, Jordan JM. IL-1 receptor antagonist gene as a predictive biomarker of progression of knee osteoarthritis in a population cohort. Osteoarthritis Cartilage. 2013;21:930–938.

Yang SA. Association of TLR6 single nucleotide polymorphisms and clinical features of ischemic stroke in Korean population. J Exerc Rehabil. 2013;9:526–531.

Table 1.

Clinical characteristics in overweigh/obese and control subjects

	Overweigh/obese	Controls
Total number (n)	122	123
Male/female (n)	88/34	46/77
Age (mean age±SD)	43.5±14.2	35.4±11.3
BMI (kg/m²)	25.6±2.3	20.6±1.3
Blood pressure (mmHg)
SBP	130.9±15.8	115.8±14.4
DBP	80.4±10.3	70.6±9.6

SD, standard deviation; n, number of subjects; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.

Table 2.

Primer sequences for each SNP

SNPs	Sense (5’-3’)	Anti-sense (5’-3’)
rs4251961 -828 T> C	CTGGTCTGCTCCTTCCTCTCTA	AGCTTCATGTCTCTGCATTCTG
rs315952 Ser133Ser	TGGCATTTCCCCTGTACTAACT	TCCTCCTGGAAGTAGAATTTGG

SNP, single nucleotide polymorphism.

Table 3.

Genotype and allele frequencies of IL1RN SNPs in overweigh/obese and control subjects

SNP	Genotype	Controls	Overweigh/obese	Models	OR (95% CI)	P	Fisher’s exact P

		n (%)	n (%)
rs4251961	T/T	102 (82.9)	104 (85.2)	Codominant1	0.78 (0.36–1.67)	0.52
-828 T> C	T/C	20 (16.3)	18 (14.8)	Codominant2	0.00 (0.00–NA)	NA	0.50
	C/C	1 (0.8)	0 (0.0)	Dominant	0.75 (0.35–1.61)	0.46
				Recessive	0.00 (0.00–NA)	NA	1.00
				Log-additive	0.74 (0.35–1.55)	0.42
	T	224 (91.1)	226 (92.6)		1
	C	22 (8.9)	18 (7.4)		0.81 (0.42–1.55)	0.53
rs315952	C/C	41 (33.3)	39 (32.0)	Codominant1	1.29 (0.69–2.42)	0.43
Ser133Ser	T/C	65 (52.9)	62 (50.8)	Codominant2	1.04 (0.44–2.44)	0.93
	T/T	17 (13.8)	21 (17.2)	Dominant	1.22 (0.67–2.22)	0.51
				Recessive	0.89 (0.41–1.92)	0.77
				Log-additive	1.07 (0.71–1.61)	0.76
	C	147 (59.8)	140 (57.4)		1
	T	99 (40.2)	104 (42.6)		1.10 (0.77–1.58)	0.59

SNP, singe nucleotide polymorphism; OR, odds ratio; CI, confidence interval; NA, not applicable. The P values were calculated from logistic regression analysis adjusting sex and age.

Table 4.

Haplotype analysis in IL1RN SNPs

Haplotype	Frequency	Controls		Overweigh/obese		Chi Square	P

		+	−	+	−
TC	0.57	143.1	102.9	135.8	108.2	0.32	0.57
TT	0.35	80.9	165.1	90.2	153.8	0.90	0.34
CT	0.07	18.1	227.9	13.8	230.2	0.59	0.44
CC	0.02	3.9	242.1	4.2	239.8	0.02	0.90

The haplotype consists of rs4251961 and rs315952.

Table 5.

Genotype and allele frequencies of IL1RN SNPs in overweigh/obese with non-hypertension and overweigh/obese with hypertension

SNP	Genotype	Overweigh/obese with non-hypertension	Overweigh/obese with hypertension	Models	OR (95% CI)	P

		n (%)	n (%)
rs4251961	T/T	82 (83.7)	34 (85.0	Codominant1	0.80 (0.28–2.28)	0.67
-828 T> C	T/C	16 (16.3)	6 (15.0
	C/C	0 (0.0)	0 (0.0)
	T	180 (91.8)	74 (92.5)		1
	C	16 (8.2)	6 (7.5)		0.91 (0.34–2.42)	0.85
	C/C	36 (36.7)	6 (15.0)	Codominant1	4.98 (1.74–14.19)	0.003
	C/T	45 (45.9)	27 (67.5)	Codominant2	2.39 (0.68–8.36)	0.17
rs315952	T/T	17 (17.4)	7 (17.5)	Dominant	3.98 (1.48–10.74)	0.0029
Ser133Ser				Recessive	0.86 (0.32–2.31)	0.76
				Log-additive	1.60 (0.93–2.77)	0.09
	C	117 (59.7)	39 (48.7)		1
	T	79 (40.3)	41 (51.3)		1.56 (0.92–2.63)	0.08

SNP, singe nucleotide polymorphism; OR, odds ratio; CI, confidence interval. The P values were calculated from logistic regression analysis adjusting sex and age.